Definium Therapeutics (NASDAQ:DFTX – Get Free Report) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday, Wall Street Zen reports.
A number of other research firms also recently commented on DFTX. Piper Sandler reissued an “overweight” rating and set a $75.00 price objective (up from $73.00) on shares of Definium Therapeutics in a report on Friday, August 7th. Wells Fargo & Company increased their target price on shares of Definium Therapeutics from $68.00 to $72.00 and gave the company an “overweight” rating in a report on Thursday, August 13th. Robert W. Baird lifted their price target on shares of Definium Therapeutics from $75.00 to $79.00 and gave the company an “outperform” rating in a research report on Tuesday, September 15th. Canaccord Genuity Group set a $78.00 price target on shares of Definium Therapeutics and gave the company a “buy” rating in a research report on Tuesday, September 15th. Finally, HC Wainwright reissued a “buy” rating and set a $70.00 price target on shares of Definium Therapeutics in a research note on Monday, September 14th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Definium Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $66.24.
Get Our Latest Stock Analysis on DFTX
Definium Therapeutics Stock Performance
NASDAQ:DFTX opened at $32.08 on Friday. The company has a quick ratio of 15.53, a current ratio of 15.53 and a debt-to-equity ratio of 0.04. Definium Therapeutics has a fifty-two week low of $10.46 and a fifty-two week high of $49.70. The stock has a market cap of $4.39 billion, a PE ratio of -10.32 and a beta of 2.23. The firm’s fifty day simple moving average is $36.07 and its 200-day simple moving average is $30.38.
Definium Therapeutics (NASDAQ:DFTX – Get Free Report) last announced its quarterly earnings results on Monday, November 9th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.09. Analysts expect that Definium Therapeutics will post -2.94 earnings per share for the current fiscal year.
Insider Transactions at Definium Therapeutics
In other news, insider Mark Sullivan sold 14,051 shares of Definium Therapeutics stock in a transaction on Friday, September 25th. The stock was sold at an average price of $36.57, for a total transaction of $513,845.07. Following the completion of the transaction, the insider owned 494,228 shares of the company’s stock, valued at $18,073,917.96. The trade was a 2.76% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Matthew Wiley sold 3,097 shares of the business’s stock in a transaction dated Friday, September 25th. The stock was sold at an average price of $36.57, for a total transaction of $113,257.29. Following the completion of the sale, the insider owned 359,036 shares in the company, valued at $13,129,946.52. This represents a 0.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 71,098 shares of company stock worth $2,626,115. Corporate insiders own 2.40% of the company’s stock.
Hedge Funds Weigh In On Definium Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP acquired a new stake in Definium Therapeutics during the 2nd quarter valued at $138,755,000. Russell Investments Group Ltd. increased its position in Definium Therapeutics by 116.1% during the third quarter. Russell Investments Group Ltd. now owns 331,702 shares of the company’s stock worth $12,647,000 after buying an additional 178,225 shares in the last quarter. Seven Fleet Capital Management LP purchased a new position in Definium Therapeutics during the second quarter worth $6,992,000. Moody Aldrich Partners LLC raised its holdings in shares of Definium Therapeutics by 191.8% in the third quarter. Moody Aldrich Partners LLC now owns 148,870 shares of the company’s stock worth $5,666,000 after acquiring an additional 97,845 shares during the last quarter. Finally, Voya Investment Management LLC raised its holdings in shares of Definium Therapeutics by 74.9% in the third quarter. Voya Investment Management LLC now owns 166,443 shares of the company’s stock worth $6,335,000 after acquiring an additional 71,277 shares during the last quarter. Institutional investors and hedge funds own 27.91% of the company’s stock.
About Definium Therapeutics
Definium Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026.
See Also
- Five stocks we like better than Definium Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Definium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Definium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
